PIs: Wouter Hoerfsloot, Jakko van Ingen, Arthur Lemson (Nijmegen, Netherlands)
Mycobacterium avium complex (MAC) is the most frequent causative species that results in nontuberculous mycobacterial pulmonary disease (NTM-PD). Current treatment outcomes for MAC-PD are unsatisfactory with sputum culture conversion rates between 50-70%.The high prevalence of drug toxicity and low adherence to guideline-based treatment (GBT) are key reasons for the limited treatment success. Hence, there is an unmet need for prospective data on effectiveness of, adherence and adjustments to MAC-PD treatment regimens. By collaborating with NTM-NET and ESGMYC affiliated medical centers, we enable systematic, prospective data collection of an international MAC-PD cohort.
International MAC-PD cohort enrolls MAC-LD patients starting antimycobacterial treatment into a prospective, international data-registry to assess the culture conversion rate after 6 months of antimycobacterial treatment, adverse drug reactions and treatment modifications.
More Information
International MAC-PD cohort
A Prospective, Multicenter, Single-arm MAC-PD Cohort: a NTM-NET and ESGMYC Collaborative Study